BridgeMD
New treatment option for HPV-Related Cervical Carcinoma
Official title Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk HPV Infection
ClinicalTrials.gov ID: NCT06052033
What this study is testing
- What it's testing
- Non-RCT clinical trial comparing 5-ALA photodynamic therapy and CO2 laser for persistent high-risk HPV-related low-grade cervical lesions.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65, women only
You may be able to join if
- Aged 18-65 years old with a history of sexual activity.
- Subclinical infected individuals who have been confirmed as HR-HPV positive (if there is the same positive type in the typing test) for more than 1...
- Patients diagnosed with LSIL by pathological examination of cervical biopsy under colposcopy with an interval of more than 1 year.
- No fundamental diseases of important organs.
- Agree to receive treatment and/or follow-up according to regulations and sign an informed consent form.
You likely can't join if
- HR-HPV persistent infection.
- A total hysterectomy has been performed.
- Concomitant endometrial cancer, ovarian cancer, and other reproductive tract tumors.
- Complicated with abnormal heart, liver, and kidney functions, immune dysfunction, or immune system diseases such as systemic lupus erythematosus...
- Using drugs such as immunosuppressants, antiviral agents, and glucocorticoids.
- Pregnant and lactating women.
See the full eligibility criteria
- Aged 18-65 years old with a history of sexual activity.
- Subclinical infected individuals who have been confirmed as HR-HPV positive (if there is the same positive type in the typing test) for more than 1 year using HPV typing test, HPV E6/E7 mRNA test, HPV DNA test, and...
- Patients diagnosed with LSIL by pathological examination of cervical biopsy under colposcopy with an interval of more than 1 year.
- No fundamental diseases of important organs.
- Agree to receive treatment and/or follow-up according to regulations and sign an informed consent form.
- There has been no history of using other drugs related to HPV infection in the past 3 months.
- HR-HPV persistent infection.
- A total hysterectomy has been performed.
- Concomitant endometrial cancer, ovarian cancer, and other reproductive tract tumors.
- Complicated with abnormal heart, liver, and kidney functions, immune dysfunction, or immune system diseases such as systemic lupus erythematosus (SLE).
- Using drugs such as immunosuppressants, antiviral agents, and glucocorticoids.
- Pregnant and lactating women.
- Acute reproductive tract inflammation.
- Diabetes patients with uncontrolled blood sugar.
- Patients who do not receive full treatment and follow-up.
- Those who fail to sign the informed consent form.
The study team makes the final eligibility decision.
Where it's taking place
- Wenzhou, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Wenzhou, Zhejiang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.